EUVIMEDEUVIMED entdecken
Crossref

Vericiguat as an adjunct to temozolomide therapy improves behavioral and tumor outcomes in experimental glioblastoma

Fatemeh Rahmani Niya, Hamideh Bashiri, Ladan Emadi, Hossein Jonaidi, Shahrzad Azizi

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05539-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Fatemeh Rahmani Niya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Sciences, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Brain Neoplasms, Behavior, Animal. Die Arbeit nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is an aggressive brain tumor with limited effective therapies. The standard agent, Temozolomide (TMZ) though beneficial, often induces neurocognitive side effects that compromise quality of life. This study examined whether combining Vericiguat; a soluble guanylate cyclase stimulator, with standard or reduced TMZ doses could enhance antitumor efficacy and behavioral outcomes while reducing adverse effects in a rat model of GBM. 80 male Wistar rats received intracerebral injections of C6 glioma cells and were assigned to eight groups: Sham, Tumor, Vehicle, TMZ 3.75 mg/kg, TMZ 7.5 mg/kg, Vericiguat 0.5 mg/kg, and their combinations. Behavioral assessments (open field, elevated plus maze, rotarod, passive avoidance, and social interaction) were performed on days 20-24. On day 25, brain tissues were analyzed histologically and immunohistochemically (Ki-67). Survival was monitored for three months. Combination therapy significantly improved anxiety-like behavior, motor coordination, learning, memory, and social interaction compared with untreated tumor-bearing rats. Co treatment also extended survival, reduced tumor proliferation (lower Ki-67 expression), and preserved brain tissue structure. Vericiguat combined with low-dose TMZ produced synergistic effects on tumor suppression and neurocognitive recovery in GBM rats. These findings suggest that Vericiguat may enhance TMZ efficacy, enabling dose reduction and minimizing TMZ induced neurotoxicity while maintaining therapeutic effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaBrain NeoplasmsBehavior, AnimalAntineoplastic Combined Chemotherapy ProtocolsAnimalsMaleRats, WistarCell Line, TumorRatsAntineoplastic Agents, AlkylatingBrainMaze LearningMotor ActivityCell Proliferation

Stichwörter der Autor:innen

Behavioural testsCognitive functionGlioblastomaTemozolomideVericiguat

Substanzen

TemozolomideAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Basic Sciences, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran.
  • Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran. h.bashiri@kmu.ac.ir.
  • Department of Basic Sciences, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran. ladan.emadi@ut.ac.ir.
  • Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran. ladan.emadi@ut.ac.ir.
  • Department of Pathobiology, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran.

Zitieren

APA

Niya, F. R., Bashiri, H., Emadi, L., Jonaidi, H., & Azizi, S. (2026). Vericiguat as an adjunct to temozolomide therapy improves behavioral and tumor outcomes in experimental glioblastoma. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05539-8

Vancouver

Niya FR, Bashiri H, Emadi L, Jonaidi H, Azizi S. Vericiguat as an adjunct to temozolomide therapy improves behavioral and tumor outcomes in experimental glioblastoma. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05539-8

BibTeX
@article{Niya2026,
  author = {Niya, Fatemeh Rahmani and Bashiri, Hamideh and Emadi, Ladan and Jonaidi, Hossein and Azizi, Shahrzad},
  title = {Vericiguat as an adjunct to temozolomide therapy improves behavioral and tumor outcomes in experimental glioblastoma},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05539-8}
}
Kostenlos starten →